Ozempic, Wegovy, and Mounjaro: Weighing the Benefits and Risks of GLP-1 Agonists

Physician-reviewed GLP-1 safety guide

GLP-1 Benefits and Risks: What Patients Should Know

Semaglutide and tirzepatide can produce major weight loss and meaningful metabolic benefits, but they are prescription medications with real side effects, contraindications and monitoring needs.

Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

Which medications are we talking about?

Semaglutide is the active ingredient in Wegovy and Ozempic. Tirzepatide is the active ingredient in Zepbound and Mounjaro. Wegovy and Zepbound are the principal obesity-treatment brands, while Ozempic and Mounjaro are primarily diabetes products with their own labeled indications.

Tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a GLP-1-only drug, but it is commonly grouped with GLP-1 medications in patient discussions because of its similar clinical use in obesity and diabetes care.

What are the main benefits?

The most established benefits are weight reduction, appetite control, improved glucose regulation and improvement in several obesity-related risk factors. In clinical trials, semaglutide and tirzepatide have produced far greater average weight loss than older lifestyle-only control groups.

Tirzepatide has produced greater average weight loss than semaglutide in direct randomized comparison. See our separate tirzepatide vs. semaglutide comparison for that question.

Do GLP-1 medications reduce cardiovascular risk?

Some do in specific populations. Wegovy has an FDA indication to reduce the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity. Other GLP-1-class drugs have separate cardiovascular indications in diabetes populations.

That does not mean every GLP-1 medication should be described as a universal heart-protection drug. Benefits depend on the specific product, diagnosis and patient population studied.

What about sleep apnea?

Zepbound has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. That is a disease-specific benefit of tirzepatide and should not be generalized to every GLP-1 medication.

What are the most common side effects?

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, abdominal discomfort and reduced appetite. These are often more noticeable during initiation or dose escalation.

Gradual titration helps many patients tolerate therapy, but “start low and go slow” does not eliminate every adverse effect. Dose changes should follow the prescribing plan rather than patient-driven escalation.

What serious risks should patients know about?

Important warnings vary by product but can include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, hypoglycemia when combined with certain diabetes medications, and allergic reactions.

These events are much less common than nausea or constipation, but they matter because early recognition can prevent complications.

What about thyroid cancer warnings?

Semaglutide and tirzepatide product labels carry boxed warnings regarding thyroid C-cell tumors observed in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The rodent findings do not establish that these drugs cause medullary thyroid cancer in humans, but the labeled contraindications should still be followed.

Can GLP-1 medications cause gastroparesis?

These medications slow gastric emptying and can cause significant gastrointestinal symptoms in some patients. They are generally not appropriate for patients with severe gastroparesis, and persistent vomiting, severe abdominal symptoms or inability to maintain hydration should prompt medical evaluation.

Observational studies do not establish a single risk estimate that applies to every patient.

Can they cause pancreatitis?

Acute pancreatitis is an important labeled warning. Patients with severe, persistent abdominal pain—especially pain radiating to the back—with or without vomiting should seek prompt medical evaluation.

A history of pancreatitis requires individualized risk assessment rather than automatic assumptions either for or against treatment.

What about gallstones and gallbladder disease?

Rapid weight loss itself can increase gallstone risk, and GLP-1-based therapies also carry warnings regarding gallbladder events. New right-upper-abdominal pain, fever, jaundice or persistent nausea should be evaluated.

Can GLP-1 medications cause kidney problems?

The medication itself is not typically directly toxic to the kidneys, but prolonged vomiting or diarrhea can cause dehydration and acute kidney injury. Patients who cannot keep fluids down need medical attention, particularly if they already have kidney disease.

Do they cause muscle loss?

Some lean mass is commonly lost during substantial weight reduction, regardless of the method used. Body-composition studies with GLP-1 therapy show that lean tissue can decline along with fat mass.

The practical response is not to avoid medically appropriate weight loss, but to emphasize adequate protein intake, resistance training and preservation of physical function. See our separate article on muscle preservation during GLP-1 therapy.

Do GLP-1 medications reduce thirst?

Some patients report drinking less because appetite and overall intake fall, but reduced thirst should not be presented as a universal pharmacologic effect. The safer message is to monitor hydration—especially when nausea, vomiting or diarrhea is present.

Are claims about Alzheimer’s, Parkinson’s or cancer treatment proven?

No. Research into neurodegenerative disease, inflammation and cancer biology is active, but GLP-1 medications should not be marketed as established treatments for Alzheimer’s disease, Parkinson’s disease or cancer unless and until specific indications are supported by adequate evidence and regulatory approval.

Who should avoid these medications?

Contraindications and precautions depend on the specific product, but important examples include personal or family history of medullary thyroid carcinoma, MEN2, prior serious hypersensitivity to the drug, pregnancy for intentional weight loss, and severe gastrointestinal disease in some circumstances.

Patients taking insulin or sulfonylureas may also need diabetes-medication adjustment because hypoglycemia risk can increase when therapies are combined.

What about pregnancy?

Intentional pharmacologic weight loss is not appropriate during pregnancy. Women planning pregnancy should follow the current product-specific discontinuation guidance because semaglutide and tirzepatide have different recommendations.

Are compounded GLP-1 medications the same as FDA-approved products?

No. Compounded semaglutide and tirzepatide are not FDA-approved generic equivalents of Wegovy, Ozempic, Zepbound or Mounjaro. FDA does not review compounded drugs for safety, effectiveness or quality before marketing.

FDA has also warned about dosing errors, fraudulent products and misleading claims involving compounded GLP-1 drugs. For the regulatory details, see our dedicated semaglutide compounding update and tirzepatide compounding update.

What should patients ask before starting?

• What diagnosis and FDA-approved indication are we treating?
• Which specific drug and brand is being prescribed?
• What side effects should trigger a call or urgent evaluation?
• How will dose escalation be handled?
• How will protein intake, resistance training and hydration be supported?
• What is the full monthly cost, including medication, visits, labs, shipping and higher doses?
• If the medication is compounded, why is a compounded preparation clinically necessary?

Frequently asked questions

Are GLP-1 medications safe?

They have favorable benefit-risk profiles for appropriately selected patients, but they can cause common and serious adverse effects and should be prescribed with appropriate screening and follow-up.

Which is safer: semaglutide or tirzepatide?

Both have broadly similar gastrointestinal tolerability issues and overlapping serious warnings. The better option depends on individual risk factors, disease-specific indications and prior response.

Do GLP-1 drugs damage the stomach permanently?

Most gastrointestinal side effects are reversible, but severe or persistent symptoms warrant evaluation. Patients with known severe gastroparesis may not be good candidates.

Do GLP-1 medications cause muscle wasting?

They can be associated with loss of some lean mass during weight reduction, but this is not unique to GLP-1 therapy. Resistance training and adequate protein are important countermeasures.

Are GLP-1 medications addictive?

No. They do not cause a classic addictive or drug-withdrawal syndrome. However, appetite and weight often increase again after treatment stops because the medication’s biological effects are no longer present.

Medical and regulatory references

• FDA: Concerns with unapproved GLP-1 drugs used for weight loss
• STEP 1: Semaglutide in adults with overweight or obesity
• SURMOUNT-1: Tirzepatide once weekly for obesity
• SURMOUNT-5: Tirzepatide compared with semaglutide for obesity

This article is educational and does not replace individualized medical advice or current product labeling.